BioCentury | Apr 29, 2020
Product Development

India emerging as major COVID-19 vaccine manufacturer

...is being developed by Zydus unit Etna Biotech, an Italian company that Zydus acquired from Crucell N.V....
BioCentury | Mar 3, 2020
Product Development

Latest actions see Europe at heart of global response to COVID-19

...rAdV) vector platform the company is using came from its 2011 acquisition of Dutch biotech Crucell N.V....
BioCentury | Nov 8, 2019
Finance

Van Herk’s DCprime ready to boost its cell-based cancer vaccine

...$2.2 billion acquisition of Crucell N.V. by Johnson & Johnson (NYSE:JNJ) in 2010. Van Herk was Crucell’s...
BioCentury | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

...including the MedImmune Inc. unit of AstraZeneca plc, the Genentech Inc. unit of Roche, the Crucell N.V....
BioCentury | Apr 19, 2018
Translation in Brief

One-two punch for West Nile

...treat West Nile fever. The therapy is a combination of undisclosed FDA-approved products. In 2008, Crucell N.V....
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...UCB S.A. (Euronext:UCB) in 2004 for £1.5 billion ($2.6 billion) • Lack of innovative pipeline Crucell N.V....
BioCentury | Feb 25, 2017
Product Development

mRNA test kitchens

...C) Includes $50 million equity investment; (D) Includes $25 million equity investment; (E) Through its Crucell N.V....
...Jan-14 CureVac AG Johnson & Johnson (NYSE:JNJ) (E) Influenza CureVac will develop flu vaccines using Crucell's...
BioCentury | Dec 10, 2016
Company News

Management tracks

...Lahr has held several advisory and director roles since serving as chief strategy officer at Crucell N.V....
BioCentury | Aug 8, 2016
Clinical News

Ad26: Completed Phase I/IIa enrollment

...a prime-boost vaccination strategy and leverages its AdVac technology gained through its 2011 acquisition of Crucell N.V....
BioCentury | Aug 8, 2016
Clinical News

Ad26: Phase I/IIa started

...a prime-boost vaccination strategy and leverages its AdVac technology gained through its 2011 acquisition of Crucell N.V....
Items per page:
1 - 10 of 492
BioCentury | Apr 29, 2020
Product Development

India emerging as major COVID-19 vaccine manufacturer

...is being developed by Zydus unit Etna Biotech, an Italian company that Zydus acquired from Crucell N.V....
BioCentury | Mar 3, 2020
Product Development

Latest actions see Europe at heart of global response to COVID-19

...rAdV) vector platform the company is using came from its 2011 acquisition of Dutch biotech Crucell N.V....
BioCentury | Nov 8, 2019
Finance

Van Herk’s DCprime ready to boost its cell-based cancer vaccine

...$2.2 billion acquisition of Crucell N.V. by Johnson & Johnson (NYSE:JNJ) in 2010. Van Herk was Crucell’s...
BioCentury | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

...including the MedImmune Inc. unit of AstraZeneca plc, the Genentech Inc. unit of Roche, the Crucell N.V....
BioCentury | Apr 19, 2018
Translation in Brief

One-two punch for West Nile

...treat West Nile fever. The therapy is a combination of undisclosed FDA-approved products. In 2008, Crucell N.V....
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...UCB S.A. (Euronext:UCB) in 2004 for £1.5 billion ($2.6 billion) • Lack of innovative pipeline Crucell N.V....
BioCentury | Feb 25, 2017
Product Development

mRNA test kitchens

...C) Includes $50 million equity investment; (D) Includes $25 million equity investment; (E) Through its Crucell N.V....
...Jan-14 CureVac AG Johnson & Johnson (NYSE:JNJ) (E) Influenza CureVac will develop flu vaccines using Crucell's...
BioCentury | Dec 10, 2016
Company News

Management tracks

...Lahr has held several advisory and director roles since serving as chief strategy officer at Crucell N.V....
BioCentury | Aug 8, 2016
Clinical News

Ad26: Completed Phase I/IIa enrollment

...a prime-boost vaccination strategy and leverages its AdVac technology gained through its 2011 acquisition of Crucell N.V....
BioCentury | Aug 8, 2016
Clinical News

Ad26: Phase I/IIa started

...a prime-boost vaccination strategy and leverages its AdVac technology gained through its 2011 acquisition of Crucell N.V....
Items per page:
1 - 10 of 492